enGene Therapeutics Inc. develops non-viral genetic medicines for delivery to mucosal tissues and other organs. The company’s lead program is detalimogene voraplasmid, also known as detalimogene, for non-muscle invasive bladder cancer. Detalimogene is being evaluated in the multi-cohort LEGEND Phase 2 trial, including a pivotal cohort in high-risk, Bacillus Calmette-Guérin-unresponsive patients with carcinoma in situ, with or without concomitant papillary disease.
Recurring enGene news includes LEGEND clinical data, FDA designation and manufacturing-readiness updates, business and financial results, debt and equity financing activity, investor-conference participation, and corporate matters such as the completed name change from enGene Holdings Inc. to enGene Therapeutics Inc. The company’s common shares trade on Nasdaq under ENGN, and its listed warrants trade under ENGNW.
enGene (Nasdaq: ENGN) plans to initiate a biologics license application for detalimogene by year-end 2026 following updated Phase 2 LEGEND results. The pivotal cohort studied high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin treatment. At the October 29 cutoff, complete response at any time reached 56% in 120 efficacy-evaluable patients, versus 54% in April 2026. The preliminary estimate of responses lasting at least 12 months rose to 43% from 25%; preliminary median response duration increased to 10.1 months from 8.6 months. The 12-month complete response rate rose to 24% from 13%.
Among 125 safety-assessed patients, 2% had serious treatment-related adverse events. FDA discussions established alignment on the efficacy-evaluable population. enGene expects to complete its application in the first half of 2027, with potential approval in 2027.
enGene (Nasdaq: ENGN) appointed Erik T. Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026.
The appointments precede the company's planned submission of a Biologics License Application, a request for regulatory approval, for detalimogene before year-end 2026. enGene anticipates potential approval in 2027. The investigational bladder cancer therapy is being evaluated in the ongoing Phase 2 LEGEND trial, including a pivotal cohort in patients whose disease has not responded to BCG treatment. Goluboff succeeds interim Chief Medical Officer Bill Grossman, who remains a board member.
The board approved employment inducement grants of 450,000 stock options for Goluboff and 500,000 for Duncan. The options will vest over four years, subject to continued employment.
enGene Therapeutics (ENGN) announced that management will participate in investor conference fireside chats on November 16 and November 19, 2026.
The UBS Global Biopharma Conference session is at 3:20 p.m. GMT / 10:20 a.m. ET. The Jefferies Global Healthcare Conference in London session is at 10:30 a.m. GMT / 5:30 a.m. ET. Live webcasts will be available through enGene’s investor website and archived for 90 days.
enGene (ENGN) will host a webinar on October 15, 2026, covering bladder cancer treatment decisions and preclinical data supporting further clinical development.
The webinar begins at 10:00 AM ET and features Colorado Urology physicians David J. Cahn and Suzanne B. Merrill. Discussion will cover a surfactant bladder rinse before detalimogene, an investigational gene therapy. An additional cohort using this approach is currently enrolling in the ongoing LEGEND trial.
enGene Therapeutics (ENGN) reported third quarter 2026 results and advanced detalimogene toward a planned Biologics License Application (BLA) filing.
For the quarter ended July 31, 2026, cash, cash equivalents and marketable securities were $266.3 million, up from $202.3 million at October 31, 2025. Total operating expenses were $34.0 million versus $29.9 million a year earlier, reflecting lower research and development spending and higher general and administrative costs, both influenced by workforce reduction-related items. Net loss attributable to common shareholders was $32.5 million, or $0.47 per share, compared with $29.0 million, or $0.57 per share, in the prior-year quarter.
Clinically, detalimogene’s pivotal LEGEND Cohort 1 previously showed a 54% complete response rate and 3.2% progression to muscle-invasive disease. enGene plans a data update, an FDA pre-BLA meeting, and initiation of BLA submission for detalimogene in 4Q 2026, with a potential FDA decision in 2027.
enGene Therapeutics (Nasdaq: ENGN) announced that management will participate in three September 2026 investor events: the Wells Fargo 21st Annual Healthcare Conference on September 8 at 10:15 a.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:00 a.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 1:30 p.m. ET.
According to enGene, all sessions will be accessible via live webcast on the company’s website under the Investors > Events and Presentations section and will remain archived for 90 days.
enGene (Nasdaq: ENGN) will host a virtual key opinion leader (KOL) webinar on Tuesday, August 11, 2026 at 11:00 AM ET. The event will feature urologic oncologist Neal Shore, MD, FACS alongside enGene management.
According to enGene, the webinar will cover the evolving non-muscle invasive bladder cancer (NMIBC) treatment landscape, including future treatment paradigms, therapy sequencing, community urology practice insights, treatment choice drivers, and pricing and reimbursement dynamics. A live Q&A will follow. Live and replay access will be available via the “Events and Presentations” page in the Investors section of enGene’s website.
enGene Therapeutics (Nasdaq: ENGN) announced a Board transition as it prepares for key regulatory and commercial milestones for its lead asset, detalimogene voraplasmid, in high-risk non-muscle invasive bladder cancer (NMIBC). Michael Heffernan, a biopharma executive with over 30 years of experience and founder of Collegium Pharmaceutical, becomes Chairman after serving on the Board since July 2025, while longtime Chairman Dr. Richard Glickman steps down from the role.
Detalimogene is being evaluated in the ongoing Phase 2 LEGEND trial, whose pivotal Cohort 1 includes 125 BCG-unresponsive NMIBC patients with carcinoma in situ. enGene is planning a pre-BLA meeting and initiation of a BLA submission for detalimogene in the second half of 2026, with a potential FDA approval in 2027.
enGene (Nasdaq: ENGN) reported Q2 2026 results and a major business reset. LEGEND pivotal Cohort 1 of detalimogene in high-risk BCG-unresponsive NMIBC showed a 54% complete response rate and 3.2% progression, with low treatment-related discontinuations.
The company plans FDA engagement and initiation of a BLA filing for detalimogene in 2H 2026, targeting a potential FDA decision in 2027. A surfactant plus detalimogene cohort has begun enrolling. enGene is cutting its workforce by about 50%, halting enrollment in LEGEND Cohorts 2a, 2b and 3, and announcing multiple executive departures while maintaining key functions. Cash, cash equivalents and marketable securities totaled $285.2 million; quarterly operating expenses were $32.0 million and net loss was $30.2 million, or $0.43 per share.
enGene (Nasdaq: ENGN) reported updated interim results from the Phase 2 LEGEND pivotal cohort in BCG-unresponsive NMIBC (125 patients) on May 7, 2026. Key metrics: 54% complete response (CR) at any time, 43% CR at 6 months, 12‑month KM DoR 25%, and 3.2% progression to muscle‑invasive disease. Safety: 55% experienced treatment-related adverse events, mostly Grade 1–2. enGene will discuss results on a May 7 webcast and plans further FDA engagement toward a potential BLA.